Nov 14, 2022 / 10:00PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Lexicon Pharmaceuticals Inc. full stated results from RELIEF-DPN-1. (Operator Instructions) This call is being recorded on November 14, 2022.
I would now like to turn the conference over to Mike Kelly. Please go ahead, sir.
Mike Kelly -
Thank you, Andrew. Good afternoon, and welcome to the Lexicon Pharmaceuticals conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Dr. Anand Patel, Chief Medical Officer at Conquest Research.
Earlier today, Lexicon issued a press release reporting full results from the RELIEF-DPN-1 Phase II proof-of-concept study of LX9211 in painful diabetic neuropathy, which was also presented at the 16th Annual Pain Therapeutics Summit by Dr. Patel. Copy of that press release as well as a webcast of this call and the slide presentation is available on our website at
Lexicon Pharmaceuticals Inc LX9211 Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers